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[3H]Spiroperidol (spiperone) binding in the presence of mianserin, a serotonin (5-HT2) receptor antagonist, was characterized in rat 
brain using quantitative autoradiography. All binding parameters were directly determined from film densities. Competition and ki- 
netic studies revealed that [3H]spiroperidol binds to a site having characteristics of the dopamine, D2, receptor in striatum. The gener- 
al binding parameters were similar to values obtained in homogenate and swabbed section studies except as related to agonist binding 
and guanine nucleotide sensitivity. Competition studies with dopamine revealed biphasic competition curves with a K h of 8.23 nM and 
a K l of 12.3/~M. The percentage of high-affinity sites was 90%. Guanine nucleotides (1/~M guanylyl-imidodiphosphate) completely 
converted the high-affinity site to a low-affinity site. Quantitative regional distribution studies revealed high binding in striatum, olfac- 
tory tubercle and nucleus accumbens, with lower binding in other dopamine innervated regions including frontal and cingulate cortex. 
[3H]Spiroperidol was also found to bind to a spirodecanone site with an anatomical localization distinct from the dopamine and seroto- 
nin systems and in a region (entorhinal cortex) not previously reported. This report provides a detailed pharmacologic and regional 
characterization of [3H]spiroperidol binding to D 2 receptor in rat brain using quantitative autoradiography to determine all binding pa- 
rameters. This report also demonstrates an increased percentage of sites in the high-affinity state of the D 2 receptor in tissue sections 
and increased affinity of the guanine regulatory protein for guanine nucleotides. 
INTRODUCTION 
[3H]Spiroperidol, a butyrophenone dopamine an- 
tagonist, has been used extensively to label the D 2 
dopamine receptor  subtype in homogenate  6'3°, intact 
cell 33 and autoradiographic studies 1'2'27. The D 2 re- 
ceptor is thought  to be linked to adenylate cyclase in 
an inhibitory manner  34. Agonists recognize both 
high- and low-affinity forms of  the receptor which 
can be interconverted by guanine nucleotides 7'32' 
36.38. The recent use of  quantitative autoradiography 
with other radiolabeled ligands 13'17'28'29'35'37 
prompted the adaptation of  this technique to study 
[3H]spiroperidol binding to the D 2 receptor. The abil- 
ity to perform quantitative autoradiography of  the D 2 
receptor in which all quantitative measurements 
were taken directly from the film would allow deter- 
mination of binding parameters in many anatomical- 
ly small and distinct regions in a single animal. Expe- 
riments modifying the dopamine receptor could then 
be analyzed autoradiographically in the different do- 
pamine systems including nigrostriatal, mesocortical 
and mesolimbic. The goal of this report  is to describe 
appropriate kinetic and binding conditions for using 
[3H]spiroperidol to study the D 2 receptor with quan- 
titative autoradiography. In addition, we report 
properties relating to agonist binding and guanine 
nucleotide regulation which are different f rom those 
found with the homogenate  and swabbed tissue sec- 
tion methods. 
MATERIALS AND METHODS 
Tissue preparation 
Male Sprague-Dawley  rats averaging 200 g were 
decapitated and their brains rapidly removed.  Brains 
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were mounted on chucks using Lipshaw embedding 
matrix and rapidly frozen in crushed dry ice. After 
warming to -20  °C, 20-~m cryostat sections were cut, 
thaw-mounted onto gelatin-coated microscope 
slides, dehydrated at room temperature and stored at 
-20  °C until used in assays. All slides were used with- 
in 5 days of sectioning. 
Binding assay 
All assays were performed at room temperature. 
The preincubation wash and postincubation rinse 
were performed at 4 °C. All assays used the same 
buffer consisting of 170 mM Tris-HC! at a pH of 7.70, 
120 mM NaCI, 5 mM KC1, 1 mM MgC12, 2 mM 
CaC12, 0.001% ascorbate and 1 ~M pargyline. All 
slides were given two 5-min washes in buffer and a 3-s 
dip in distilled water after incubation. After  the dip in 
distilled water the slides were fan-dried at room tem- 
perature. Mianserin (100 nM) was present in the buf- 
fer of all experiments except for mianserin competi- 
tion studies when the concentration was varied. 
Saturation studies were performed with concentra- 
tions of  [3H]spiroperidol from 0.2 to 4 nM and an in- 
cubation time of 120 min to ensure equilibrium bind- 
ing at the lowest concentration. Ligand concentra- 
tions in the incubation medium were measured be- 
fore and after incubation to ensure that free ligand 
concentration was constant. Competi t ion and distri- 
bution studies were performed at a [3H]spiroperidol 
concentration of 0.50 nM. Incubation time was 60 
min for competition and distribution studies and var- 
ied from 1 to 120 min for kinetic studies. 
Autoradiography 
Dried slides were placed in an X-ray cassette with 
t4C plastic standards previously calibrated with 3H 
brain paste sections zs and exposed to LKB Ultrofilm 
3H at 4 °C for 21 days for all studies except the distri- 
bution studies which were exposed for 28 days to al- 
low imaging of regions with a low density of D2 recep- 
tors. The Ultrofilm 3H was developed at room tem- 
perature with Kodak D19 for 3 min, stopped and 
fixed with Kodak rapid fix for 3.5 min. All binding 
data were determined directly from film densities in 
regions of interest. Films were analyzed using a pho- 
tographic enlarger and a computer  to determine opti- 
cal densities 1°. A minimum of 20 readings from each 
area were averaged and the radioactivity determined 
by a computer-generated polynomial regression 
analysis which compared film densities produced by 
tissue sections with those produced by radioactive 
standards. 
Materials 
[3H]Spiroperidol (19-26 Ci/mmol) was obtained 
from New England Nuclear (Boston) and Amersham 
Corp. (Arlington Heights, 1L), mianserin from Orga- 
non (Oss, The Netherlands), haloperidol from 
McNeil Pharmaceutical (Spring House,  MA),  (+) -  
and (-)-butaclamol  from Research Biochemicals 
Inc. (Wayland, MA) and dopamine from Sigma (St. 
Louis, MO). 
RESULTS 
Kinetic studies were performed to determine ap- 
propriate incubation and postincub~ition rinse times. 
Kinetic studies were performed at several [3H]spiro- 
peridol concentrations between 0.5 and 1 nM. The 
association rate constant as determined by a pseudo 
first-order method 3 was 0.055 _+ 0.002 min -~ (Fig. 
1A). The dissociation rate constant, as determined 
by infinite dilution after equilibrium binding, was 
0.004 _+ 0.0003 min -1 (Fig. 1B). Equilibrium for corn- 
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Fig. 1. A: association curve of [3H]spiroperidol binding to stria- 
tum. Representative association curve performed at a ligand 
concentration of 0.50 nM. kob was determined from the slope of 
In (Be-B) vs time where Be is binding at equilibrium (curve not 
shown), k I was determined as described by Bylund 3. The aver- 
age k 1 from 3 experiments was 0.055 + 0.002 min-t.nM -1. B: 
dissociation curve of [3H]spiroperidol binding to striatum. Rep- 
resentative dissociation curve at a ligand concentration of 0.50 
nM. k_ l was determined from the slope of the curve of In B/Bo 
vs time where Bo is the amount bound at equilibrium. The av- 
erage k l from 3 experiments was 0.004 _+ 0.0003 min-L 
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Fig. 2. A: Scatchard plot of [3H]spiroperidol binding to stria- 
tum. Representative Scatchard plot of binding with ligand con- 
centrations from 0.20 to 4.0 nM in the presence to 100 nM 
mianserin. Specific binding was determined by subtracting 
binding in the presence of 10 a M  dopamine from total binding. 
The K a and Bma x from two experiments was 0.170 _+ 0.006 nM 
and 0.440 + 0.010 pmol/mg protein, respectively. B: antagonist 
competition curves for [3H]spiroperidol binding to striatum. 
Representative competition curves from a single experiment 
plotted as logit % bound vs log competitor. The Iogit values 
were obtained by the formula logit (% bound) = In (% 
bound/(100-% bound)). The K i values were determined from 
the IC50 by the equation of Cheng and Prusoff 4. The average 
K,s from 3 experiments were as follows: haloperidol, 7.62 + 
0.916 nM; (+)-butaclamol, 11.28 nM; mianserin, 5.88 + 2.56 
#M; (-)-butaclamol, 11.84 +__ 1.65 #M. 
petition and distribution studies occurred by 60 min 
for [3H]spiroperidol concentrations above 0.5 nM. 
The equilibrium dissociation constant (K~) as deter- 
mined by kinetic relationship ( k J k + t )  was 0.170 _+ 
0.002 nM. 
Saturation studies revealed a K a of 0.170 + 0.006 
nM and a maximum number of binding sites (Bmax) of 
0.44 + 0.01 pmol/mg protein in striatum (Fig. 2A). 
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Fig. 3. Dopamine competition curves for [3H]spiroperidol 
binding to striatum. Representative dopamine competition 
curves from a single experiment in the absence and presence of 
1 pM GmP-PnP. Dopamine competed biphasically for [3H]spi- 
roperidol binding with a Hill slope of 0.63 _+ 0.042. In the pres- 
ence of 1 pM GmP-PnP the Hill slope was changed to 0.95 + 
0.035. The values represent the average of 3 experiments. 
single binding site in striatum in the presence of 
mianserin. Ligand concentrations measured before 
and after incubation revealed that zone 'A '  condi- 
tions were maintained at all ligand concentrations u. 
Competition curves using various antagonists re- 
vealed a rank order of potency for binding to the D 2 
receptor in tissue sections similar to that found in ho- 
mogenate studies (Fig. 2B). Haloperidol had the 
lowest K i of 7.62 + 3.16 nM. Butaclamol demon- 
strated stereospecificity with the (+)  isomer having a 
K i (11.3 _+ 1.6 nM) more than a thousand-fold lower 
than the ( - )  isomer (Ki 11.8 _+ 1.7#M). Mianserin had 
a K i of 5.88 _+ 2 .6#M for the D 2 site. The Hill slopes 
for the antagonists did not vary significantly from 
one. 
Dopamine had a biphasic pattern of competition 
with a high affinity ( K h )  of 8.2 _+ 6.3 nM and a low af- 
finity (Kt) of 12.3 _+ 8.4pM (Fig. 3). K h was higher than 
that seen in most homogenate studies. The percen- 
tage of high-affinity sites was 90%. Agonist binding 
was very sensitive to low concentrations of guanylyl- 
imidodiphosphate (GmP-PnP), with 1 #M GmP-PnP 
causing a complete shift to the low-affinity state (Fig. 
3). The Hill slope for dopamine competition changed 
from 0.63 +_ 0.04 to 0.95 +_ 0.35 in the presence of 1 
#M GmP-PnP. A complete shift to the same low-af- 
finity stare'was seen in the presence of 100 pM GTP. 
There was no change in affinity states in the presence 
of 10 BM adenylyl-imidodiphosphate (AmP-PnP). 
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Fig. 4. [3H]Spiroperidol autoradiograms of coronal sections 
through striatum. All incubations were done at a concentration 
of approximately 0.8 nM [3H]spiroperidol. A: binding without 
competing drug present to display binding to the D 2, 5-HT 2 and 
spirodecanone sites in various structures. B: binding in the 
presence of 100 nM mianserin to block binding to the 5-HT 2 re- 
ceptor. This eliminates binding to layer IV of cortex which has 
no dopamine or spirodecanone sites, and reduces binding in nu- 
cleus accumbens, olfactory tubercle and septal nuclei which 
have both D 2 and 5-HT 2 sites. C: binding in the presence of 10 
/aM dopamine to block the D 2 receptor. This leaves binding to 
the 5-HT 2 and spirodecanone sites. D: binding in the presence 
of 10/aM dopamine and 100 nM mianserin. This leaves residual 
binding in olfactory tubercle and nucleus accumbens, ot, olfac- 
tory tubercle; acc, nucleus accumbens; cot IV, layer tV cere- 
bral cortex; end, endopiriform nucleus; polc, primary olfactory 
cortex; sep, lateral dorsal septal nucleus; str, striatum; vdb, 
vertical limb of the nucleus of the diagonal band. 
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The autoradiograms in Fig. 4 show that binding to 
either the D 2 (Fig. 4B) or the 5-HT 2 (Fig. 4C) recep- 
tor can be selected with the use of an appropriate 
concentrat ion of a competitor, in  addition, [3H]spi- 
roperidol labels a spirodecanone site which is insensi- 
tive to dopamine and mianserin.  Binding to this site is 
found in the CA1 region of hippocampus with a high 
density in the pyramidal cell layer and a lower density 
in entorhinal  cortex (Fig. 5). In the presence of ex- 
cess of dopamine and mianserin there is still a small 
degree of residual binding in nucleus accumbens and 
olfactory tubercle which may represent the spirode- 
canone site as well. The distribution of the D2 site is 
summarized in Table I in terms of amount  of [3H]spi- 
roperidol bound and the amount  bound relative to 
striatum. 
DISCUSSION 
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Fig. 5. [3H]Spiroperidol autoradiogram of a horizontal section 
incubated at a [3H]spiroperidol concentration of 0.8 nM in the 
presence of 100 nM mianserin. This demonstrates binding to 
the D 2 receptor in striatum, frontal cortex and anterior cingu- 
late cortex, as well as to the spirodecanone site in hippocampus 
and entorhinal cortex, acin, anterior cingulate cortex; ent, en- 
torhinal cortex; hip, hippocampus; pref, prefrontal cortex; str, 
striatum. 
rive autoradiography to determine binding para- 
meters directly from film density. Others have dem- 
onstrated the ability to perform autoradiography 
using [3H]spiroperidol of the D 2 receptor 1,2'27. We 
have expanded this methodology to determine addi- 
tional properties of [3H]spiroperidol binding to tissue 
sections. Saturation studies reveal that [3H]spiroperi- 
dol binding is saturable with an affinity and Bma x simi- 
TABLE I 
Regional distribution of [3H]spiroperidol binding to the D 2 re- 
ceptor 
Binding was performed at a [3H]spiroperidol concentration of 
0.5 nM in the presence of 100 nM mianserin to eliminate 5-HT 2 
binding. Values represent the average of 3 separate experi- 
ments. 
Region Bound % Bound 
(pmol/mg) (relative to 
striatum) 
Striatum 0.286 + 0.063 100 
Nucleus accumbens 0.112 + 0.017 39 
Olfactory tubercle 0.218 + 0.076 76 
Mesial frontal cortex 0.060 + 0.003 21 
Anterior cingulate cortex 0.089 + 0.006 31 
Piriform cortex 0.077 + 0.038 27 
Septum 0.028 + 0.003 10 
Central amygdaloid nucleus 0.046 + 0.019 16 
Substantia nigra 0.093 + 0.004 32 
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lar to that found in a quantitative autoradiographic 
study 21 using a different D 2 receptor ligand. In two 
studies using swabbed tissue sections 26'27 the g d (0.14 
and 0.92 nM) and Bma x (63 and 447 fmol/mg protein) 
differ from each other and may be related to differ- 
ences in technique 26'27. In addition, when using 
swabbed sections to determine binding parameters, 
anatomically discrete regions having different bind- 
ing parameters are averaged together. Tissue sec- 
tions in the region containing striatum may also con- 
tain other regions having dopamine receptors includ- 
ing nucleus accumbens, olfactory tubercle and sep- 
tum. By determining values directly from film den- 
sities each area can be evaluated independently. 
Kinetic studies established that binding is reversi- 
ble, with kinetic constants producing a K d = k_l/k+l 
= 0.071 nM which is in close agreement with satu- 
ration experiments ( g  d = 0.170 nM). The kinetic 
constants determined in this study differ from those 
obtained using swabbed tissue sections 26 which sug- 
gests that kinetic parameters may vary with tech- 
nique. If other binding values are to be determined 
autoradiographically, kinetic parameters should be 
obtained densitometrically first. The competition 
studies established that the rank order of potency for 
the various antagonists agrees with that found in ho- 
mogenate studies and that binding is stereospecific 
with (+)-butaclamol having a K i more than a thou- 
sand times lower than (-)-butaclamol. Mianserin 
was shown to block both the 5-HT 2 and D2 receptor. 
A concentration of mianserin (100 nM) was selected 
that blocked all the 5-HT 2 sites as demonstrated by 
the absence of all cortical binding in layer IV (which 
is specific for serotonin sites) but was 100-fold lower 
than the ICs0 for the D2 receptor in striatum. This 
concentration agrees with the value found by others 
to displace serotonin binding without effecting dopa- 
mine binding in homogenate studies using [3H]spiro- 
perido124. 
This study also reports quantitative D 2 receptor 
density measurements in multiple brain regions 
which range from a low of 0.028 pmol/mg protein in 
septum to 0.286 pmol/mg protein in striatum at a 
[3H]spiroperidol concentration of 0.5 nM. Determi- 
nation of values in some of these brain regions would 
be technically difficult using homogenates or tissue 
section swabs. The distribution of binding of [3H]spi- 
roperidol to D 2 receptors in rat brain is consistent 
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with what is known of the dopamine systems. A 
sparse projection from substantia nigra to globus pal- 
lidus and entopeduncular nucleus has been re- 
ported2S; however, in this study binding was not 
found in those areas in films exposed for 4 weeks and 
would have a density less than 0.028 pmol/mg protein 
which is the lowest density seen in septum. The meso- 
cortical system has been reported ls'23 to project to 
the nucleus accumbens, amygdaloid complex, ante- 
rior cingulate cortex, prefrontal cortex and septal nu- 
clei. Significant binding to these areas was seen in 
this quantitative autoradiographic study. 
The binding of [3H]spiroperidol to the spirodeca- 
none site has been reported by others 19'27. This auto- 
radiographic study demonstrates the unique laminar 
distribution of that site in the hippocampus, as well 
as, an additional site, not previously reported, found 
in entorhinal cortex. In addition, there is a small 
amount of binding present in nucleus accumbens and 
olfactory tubercle in the presence of high concentra- 
tions of dopamine and mianserin which may also rep- 
resent this spirodecanone site. The significance of 
this site remains unknown, however, its location in 
only mesolimbic areas is of interest. At high [3H]spi- 
roperidol concentrations binding was also observed 
in the superficial layer next to cortex. This binding 
may represent receptors on the arachnoid mem- 
brane. 
The major pharmacological difference between 
[3H]spiroperidol binding to tissue sections and to ho- 
mogenates or swabbed sections seen in this study is 
the interaction of D 2 receptor agonists and guanine 
nucleotides. In general, the behavior of the D 2 recep- 
tor has been analogous to the fl-adrenergic sys- 
tem 16'22. In the fl-adrenergic system, antagonists bind 
to one homogeneous state of the receptor with a sin- 
gle affinity, while agonists bind to two distinct states; 
one with high affinity and one with low affinity. Gua- 
nyl nucleotides are able to shift the high-affinity state 
to a low-affinity state. In the D 2 system, agonists 
have been shown to manifest heterogeneous binding 
also. However, there remains question as to whether 
agonist binding is best modeled as a two-site 11'32 or 3- 
site 36 model. Guanine nucleotides have been shown 
to decrease the high-affinity binding of agonists to 
the D 2 receptor sA1'3639. 
In this report, we find that the use of quantitative 
autoradiography to study agonist and guanine nu- 
cleotide interactions involving the D 2 receptor dem- 
onstrates several advantages over other techniques. 
First, the percentage of D 2 sites in the high-affinity 
agonist state is approximately 90% in tissue sections. 
This contrasts with homogenate binding where the 
percentage is usually much lower, wtrying from 
2 8 %  36 tO 5 6 %  11 using dopamine as a competitor. 
There is also wide variation depending on the agonist 
used. In addition, the high-affinity site of the D 2 re-  
c e p t o r  had a K i for dopamine of 8 nM. This contrasts 
with the high-affinity Kis found in homogenate stud- 
ies which vary from 16 nM 16 to 66 nM 11 and 190 nM 32. 
A second difference between this report and oth- 
ers is the ability of GmP-PnP to cause a complete 
shift to the low-affinity state in a buffer that does not 
reduce the high-affinity state. Several reports 2°36 
failed to find a complete shift in the presence of ex- 
cess guanine nucleotides. A recent report demon- 
strated a complete shift in the presence of 120 mM 
NaCI. However, the percentage of high-affinity sites 
was only 15% in that situation ~4. 
Another difference between tissue sections and 
homogenates is the concentration of guanine nucleo- 
tide required to convert the D 2 receptor from high to 
low affinity. Most of the homogenate studies demon- 
strating this shift used a concentration of GmP-PnP 
of 100~M. In this study, a concentration of 1/~M was 
able to cause a complete shift from high to low affini- 
ty. The complete shift seen in the presence of 100/~M 
GTP, but not with 10ktM AmP-PnP verifies the selec- 
tivity of the regulation. 
In summary, in tissue sections it appears that 90% 
of the D 2 receptor sites are in the high-affinity state 
and bind dopamine with a K, of 8 nM. These sites are 
also very sensitive to guanine nucleotides since l/~M 
GmP-PnP can shift all of the high-affinity sites of the 
D 2 receptor to a low-affinity state for which dopa- 
mine has a K i of 12~M. These differences may be due 
to factors that preserve certain membrane properties 
in the tissue sections. It may reflect preservation of 
G s protein units that are damaged during homoge- 
nization, or it may reflect a stoichiometric relation- 
ship between subunits that is altered by membrane 
disruption. 
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